RhumbLine Advisers’s XTL Biopharmaceuticals XTLB Stock Holding History

RhumbLine Advisers’s Portfolio XTLB Stock Details XTLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$16.5K	Buy	6,871 +643	+10%	+$1.74K	﹤0.01%	3770
2026 Q2	$17K	Buy	6,228 +241	+4%	+$621	﹤0.01%	3837
2026 Q1	$14.4K	Sell	5,987 -1,540	-20%	-$4.88K	﹤0.01%	3760
2025 Q4	$17.5K	Buy	7,527 +3,212	+74%	+$13K	﹤0.01%	3780
2025 Q3	$20.2K	Hold	4,315	–	–	﹤0.01%	3778
2025 Q2	$20K	Buy	4,315 +1,576	+58%	+$7.65K	﹤0.01%	3795
2025 Q1	$13.6K	Hold	2,739	–	–	﹤0.01%	3788
2024 Q4	$22.6K	Buy	2,739 +1,109	+68%	+$8.43K	﹤0.01%	3790
2024 Q3	$15.8K	Buy	1,630 +234	+17%	+$2.44K	﹤0.01%	3843
2024 Q2	$13.2K	Buy	+1,396	New	+$14.3K	﹤0.01%	3940

Other funds holding XTLB

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

RhumbLine Advisers's XTLB Position: Q3 2026 in Review

RhumbLine Advisers increased its XTL Biopharmaceuticals (XTLB) stake by 10% in Q3 2026, buying an estimated $1.74K and bringing the position to 6,871 shares worth $16.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3770.

RhumbLine Advisers first reported a position in XTLB in Q2 2024 and has held it in 10 quarters since. The position peaked at $22.6K in Q4 2024. 3 funds tracked by Wall St. Rank hold XTLB as of Q3 2026.

RhumbLine Advisers held 6,871 shares of XTL Biopharmaceuticals worth $16.5K as of Q3 2026.
RhumbLine Advisers bought 643 XTL Biopharmaceuticals shares in Q3 2026, an estimated $1.74K.
XTL Biopharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #3770 holding.
RhumbLine Advisers first reported a position in XTL Biopharmaceuticals in Q2 2024 and has held it in 10 quarters since.
RhumbLine Advisers's XTL Biopharmaceuticals position peaked at $22.6K in Q4 2024.
3 funds tracked by Wall St. Rank held XTL Biopharmaceuticals as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.